- Open Access
Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma
© Li et al; licensee BioMed Central Ltd. 2006
- Received: 21 January 2006
- Accepted: 06 July 2006
- Published: 06 July 2006
Teniposide (VM-26) has been widely used in the treatment of small cell lung cancer, malignant lymphoma, breast cancer, etc. However, there are few reports on VM-26 against oral cancers. The present study was designed to identify the effect of VM-26 against oral squamous cell carcinoma in vitro, and to provide evidence for the feasibility and effectiveness of VM-26 for application to the patients with oral cancer.
Human tongue squamous cell carcinoma cell line, Tca8113, was used. Cells were incubated with different concentrations of VM-26 for a variety of time span. Cisplatin (CDDP) was employed as a control reagent. MTT assay was used to assess the inhibitory rate of Tca8113 growth. Flow cytometer (FCM), transmission electronic microscope (TEM) and fluorescence staining were employed for determining the cell apoptotic rate. Cell cycle distribution of Tca8113 incubated with VM-26 was examined by flow cytometer assay. Statistic software (SAS 6.12, USA) was used for one-way ANOVA.
The IC50 of VM-26 against Tca8113 cells was 0.35 mg/l and that of CDDP was 1.1 mg/l. The morphological changes of Tca8113 cells were observed with fluorescence microscope and TEM. Apoptotic morphological feature could be found in the nucleus. Apoptotic rate of Tca8113 cells incubated with 5.0 mg/l of VM-26 for 72 hours was 81.67% and cells waere arrested at S phase. However, when exposed to 0.15 mg/l of VM-26 for 72 hours, G2/M phase increased from 12.75% to 98.71%, while the apoptotic rate was 17.38%, which was lower than that exposed to 5.0 mg/l of VM-26.
VM-26 could significantly induce apoptosis of oral squamous cell carcinoma and inhibit cell growth. There may be another pathway to induce apoptosis of oral squamous cell carcinoma cells except for G2/M phase arrest.
- Oral Cancer
- Oral Squamous Cell Carcinoma
- Phase Arrest
- Oral Squamous Cell Carcinoma Cell
- Squamous Cell Carcinoma Cell
The 5-year survival rate was reported to reach 64.7% for patients with oral carcinomas, while that for patients at advanced stages was between 20.0% and 40.0% . As one of three main therapies, chemotherapy may be a potential method to improve the survival rate and quality of life in patients with oral cancer, especially in advanced cancers. Cancers in oral cavity are different with cancers in other regions, which means cancers in this region are less chemosensitive, and there is still no special anticancer drug available, which is a hinder for further improvement of chemotherapeutic treatment against oral cancers. Topoisomerase II (Topo II) exists ubiquitously in cells and plays an essential role in DNA replication, transcription, chromosome formation and separation of sister chromatid [2–4]. Because of its essential role in cell growth, cell-cycle, as well as the high expression in proliferating cells, this enzyme is an ideal target for cancer chemotherapeutic drug [5, 6]. Virtually every form of cancers that can be cured by systemic chemotherapy were always treated with regimens that focus on (or at least contain) drugs targeted to Topo II . Indeed drugs targeted to Topo II are now indispensable components of systemic chemotherapy schedule which could effectively cure several known types of human cancers. Teniposide (4'-demethylepipodophyllotoxin thenylidene-beta-D-glucoside, VM-26) is a podophyllotoxin derivative and was found to be able to stabilize DNA-Topo II complex in DNA replication, thus damage the DNA and induce cellular apoptosis. It has been shown that in the treatment against small cell lung cancer, malignant lymphoma, breast cancer and ovarian cancer, etc through both clinical findings from chemotherapy results and in vitro chemosensitivity test of tumor specimen, anti-tumor effect on VM-26 was stronger than other chemotherapeutic drugs [8–10]. However, there were yet few reports on VM-26 against oral cancers. The purpose of this present study was to explore the apoptosis and concomitant cell cycle progression of Tca8113 cell treated with VM-26, and to provide evidence for the feasibility and effectiveness of VM-26 for application to oral cancers clinically.
Tca8113 cell line derived from a patient with tongue squamous cell carcinoma, was used in this study and cultured in RPMI 1640 medium supplemented with 10% calf serum, 200,000 u/l penicillin and 200,000 u/l streptomycin. Cells were cultured in 25 ml culture flasks with 2 × 105 cells/ml, in humidified atmosphere with 5% CO2 at 37°C.
Drugs and reagents
VM-26 (Bristol-Myers Squibb Co. USA, List: 3075–9), was dissolved in sterile double distilled water to a concentration of 1 g/l, and stored at -20°C. Cisplatin (CDDP, Qilu Co. China, List: 9908012) was dissolved to a final concentration of 0.1 g/l. 5.0 g/l MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] was purchased from Sigma Chemical-reagent Company. Annexin V-FITC Kit (Becton-Dickinson Co., USA) was used in this experiment.
Logarithmically growing Tca8113 cells were trypsinized and made into single cell suspension then plated in 96-well culture plate at a concentration of 5 × 104 cells/well, eight columns for VM-26 and seven columns for CDDP in each plate, 3 wells in each column. After 24 hours of incubation, the medium of the 3 wells in each column were replaced with medium containing VM-26 of 0.15 mg/l, 0.5 mg/l, 1.5 mg/l, 5.0 mg/l, 15 mg/l and 45 mg/l or CDDP of 0.1 mg/l, 0.3 mg/l, 1.0 mg/l, 3.0 mg/l and 9.0 mg/l, respectively. Blank control wells were added medium without drugs. Cells were then cultured for another 24 hours, 48 hours, 72 hours, 96 hours and 120 hours. The supernatants were removed and 20 μl MTT solution was added in each well, followed with another 4 hours of culture. The supernatants were discarded carefully and 200 μl dimethyl sulphoxide (DMSO, Sigma, USA) was added and shaken vigorously to dissolve the purple precipitation formation. Optical density (OD) of each well was tested using Spectrophotometer (Bio-Tek instruments INC.) with a wavelength of 450 nm. The experiment was repeated in triplicate. The inhibitory rate (IR) of cell growth was calculated with the following formula:
IR = [(1-ODt)/ODc] × 100%
(ODt: OD of cells in treated groups; ODc: OD of cells in control groups).
Cell fluorescence staining
Cells were incubated with VM-26 of 0.15 mg/l, 0.5 mg/l, 1.5 mg/l, 5.0 mg/l and 15 mg/l for 24 hours, 48 hours, 72 hours, 96 hours and 120 hours, respectively, then washed twice in phosphate buffered saline (PBS) and centrifuged at 1000 rpm for 10 minutes. Cell concentration was adjusted as 1 × 106 cells/ml. 10 μl of fluorescence dye EB/AO was added in 100 μl cell suspension, followed with 30 minutes of incubation in dark. Cells were then observed under fluorescence microscope. Nuclei of dead cells were dyed red while nuclei in live cells were dyed green.
Observation of cell ultrastructure using TEM
Cells were cleansed using dimethylarsinic sodium, and fixed immediately with 2% glutaraldehyde for 30 minutes. The cells were then fixed with 1% osmium tetroxide for 2 hours at 4°C, dehydrated in ethanol of gradient concentrations, displaced twice using epoxy dimethylmethane, and permeated using 618 embedding solution. Ultrastructure of cell was observed and recorded using TEM Equipment (H-500, Japan).
Cell apoptosis assay
The cells were incubated with VM-26 of 0.15 mg/l, 1.5 mg/l, 5.0 mg/l and 15 mg/l for 12 hours, 24 hours, 36 hours, 48 hours and 72 hours, respectively. Then the cells and medium supernatant were collected, washed twice with cold PBS, resuspended in 100 μl 1 × binding buffer (contained in Annexin V kit), stained with 5 μl Annexin V-FITC and 5 μl PI, and tested using flow cytometer (FACScalibur, Becton-Dickinson Co., USA).
Tca8113 cells were treated with VM-26 of 0.15 mg/l, 1.5 mg/l, 5.0 mg/l and 15 mg/l for 12 hours, 24 hours, 36 hours, 48 hours and 72 hours, respectively. Then the cells were harvested, fixed in cold 70% ethanol for 30 minutes, and resuspended in 1 ml PBS. The cell suspensions were treated using 100 μl RNase of 1 g/l for 30 min, and stained with 100 μl PI of 50 mg/l in dark for 30 minutes, and then the cells were tested using FCM. The cell cycle distribution was analyzed using ModFit LT 3.0 software.
Data were analyzed with one-way ANOVA using SAS statistical software (6.12, TS20).
Dose-dependent manner of VM-26 and CDDP against Tca8113 cells
Time-dependent manner of VM-26 and CDDP against Tca8113 cells
Apoptosis assay of Tca8113 cells
The ultrastructure changes during cell death were observed compared with the feature of blank control cells (figure 4C) using TEM. The cells treated with VM-26 showed typical apoptotic phenomenon. The nucleus became smaller, karyoplasm was concentrated and karyotheca was crimpled, chromosome condensed into a semilunar shape clinging to the karyotheca and the cellular membrane (figure 4D). The results indicated that Tca8113 cells were killed by VM-26 through apoptotic induction.
Topo II has two isomers, TopoIIα and Topo IIβ. Topo IIα is cell-cycle regulated and is abundant in proliferating cells while Topo IIβ predominates in quiescent cells . High expression of Topo IIα in tumor tissue is a common phenomenon, and Topo IIα is gradually regarded as a sign to judge the extent of tumor cell proliferating [12–14]. Topo II poisons can be classified as DNA-intercalating drug and DNA-nonintercalating drug. The former can damage DNA through inserting the plane portion of its molecular structure, such as the ring of purine or pyrimidine, into the double strands of DNA where Topo II binding to interfere the enzyme religation of the nicks of the broken DNA double strands, which lead cell to death eventually. However, the mechanism of non-intercalating drug killing tumor cells is still unclear. VM-26 is a kind of non-intercalating TopoII poison. Generally speaking, drug that can inhibit Topo IIα is also capable of inhibiting Topo IIβ. However, most drugs, especially non-intercalating drugs, are more effective on Topo IIα while intercalating drugs are more effective on Topo IIβ . Chen et al  applied 8 drugs (CDDP, 5-Fu, PYM, Taxol, VM-26, E-ADM, VDS and MTX), to test the chemosensitivity of 140 oral cancer specimens before chemotherapy, finding the average inhibitory rate of VM-26 against tumor cells reached 63.76% while the inhibitory rates of other 7 drugs were less than 30.0%. These oral squamous cell carcinoma specimens seemed not sensitive to E-ADM which is an intercalating Topo II poison.
CDDP was used as a positive control drug because it was in wide clinical use and regarded as a standard chemotherapeutic drug. We chose experimental concentration of these two drugs according to their average plasma concentration because it determined their clinical effects. Both the MTT and the FCM assay indicated that, at 5.0 mg/l concentration, the potency of VM-26 inhibiting Topo II and inducing apoptosis reached plateau. In any case, 5.0 mg/l (1/3 average plasma concentration ) VM-26 could induce approximate maximum inhibitory effect on Tca8113 cells in vitro. We found that 5.0 mg/l of VM-26 could inhibit oral cancer cells significantly after 72 hours incubation; the inhibitory rate reached 92.1% at 120 hours, which was much higher than those of CDDP at the 1/3 average plasma concentration. VM-26 inhibits the growth of tumor cell in an obvious dose-dependent and time-dependent manner.
The typical apoptotic phenomenon was found in Tca8113 cells treated with VM-26 by TEM, and also, apoptosis were induced by VM-26 both dose-dependently and time-dependently. There are many pathways for cells apoptosis, including PKA/camp pathway, T cell receptor pathway, dead receptor pathway and Fas/TNFR1 associated pathway. Mo et al  found that the ability of these DNA Topo II inhibitors including VM-26 activating FasL promoter and inducing FasL expression, was correlated with their ability to cause DNA damage. When these permanent DNA breaks were present in sufficient numbers, they initiated a series of apoptosis events that ultimately culminated in cell death .
G2 phase arrest was a common phenomenon found in mammalian cells when they were treated with most DNA-damaging reagents . Such G2 arrest has been proposed to be due to induction of G2 checkpoint machinery that allows damaged DNA to be repaired before cells move to the next cell cycle stage [19, 20]. Chen et al  reported that cells treated with VM-26 of higher dosage stopped the cell cycle in S phase, but they found the cells at last be arrested in the G2/M phase if the time of incubation with drug was prolonged and assumed such S phase inhibition should be a kind of S phase retardation other than arrest. The present study showed only VM-26 of 0.15 mg/l could significantly arrest cells in G2/M phase, while VM-26 of 1.5 mg/l, 5.0 mg/l and 15 mg/l tended to stop cell progression in S phase, and initiated significant apoptosis concomitantly. Thus, this kind of apoptosis was not triggered by G2 checkpoint machinery. This study found apoptosis of cells incubated with VM-26 of 5.0 mg/l was much more than that of cells with VM-26 of 0.15 mg/l, that is, much more cells died in the S phase than cells did in G2/M phase. So, apoptosis of Tca8113 cells incubated with VM-26 might not be induced by G2/M phase arrest, apoptosis could be induced before cells reached G2 checkpoint. Cells do not always get into G2/M phase when treated with VM-26. There may be another pathway to induce apoptosis of oral carcinoma cells except traditional G2/M phase arrest.
The present study showed that Tca8113 cells were sensitive to VM-26 and provided evidences for applying VM-26 in oral cancer chemotherapy. The results also showed that low dose and high dose of VM-26 worked in different way and there existed other ways except for G2/M phase arrest.
This work was supported by Key Project of National Natural Science Foundation of China (Grant No. 30330580) and by National Natural Science Foundation of China (Grant No. 30171014, 30300388). And Supported by Science and Technology Committee of Shanghai Municipality (Grant Number: 014319359,034107002) and by Shanghai Municipal Education Commission(Y0203).
- Qiu WL: Progress and achievements in diagnosis, treatment and research of oral tumors: 10-year review. Chinese Arch Otolaryngol Head Neck Surg. 1996, 3: 57-61.Google Scholar
- Morse-Gaudio M, Risley MS: Topoisomerase II expression and VM-26 induction of DNA breaks during spermatogenesis in Xenopus Laevis. J Cell Sci. 1994, 107: 2887-2898.PubMedGoogle Scholar
- Andreassen PR, Lacroix FB, Margolis RL: Chromosomes with two intact axial cores are induced by G2 checkpoint override: evidence that DNA decatenation is not required to template the chromosome structure. J Cell Biol. 1997, 136: 29-43. 10.1083/jcb.136.1.29.PubMed CentralView ArticlePubMedGoogle Scholar
- Mo YY, Beck WT: DNA damage signals induction of Fas ligand in tumor cells. Mol Pharmacol. 1999, 55: 216-222.PubMedGoogle Scholar
- Heck MM, Earnshaw WC: Topoisomerase II, a specific marker for cell proliferation. J Cell Biol. 1986, 103: 2569-2581. 10.1083/jcb.103.6.2569.View ArticlePubMedGoogle Scholar
- Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989, 58: 351-375. 10.1146/annurev.bi.58.070189.002031.View ArticlePubMedGoogle Scholar
- Bruden DA, Osheroff N: Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta. 1998, 1400: 139-154.View ArticleGoogle Scholar
- Bepler G, O'Briant K: In vitro chemosensitivity testing of human non-small cell lung cancer cell lines. Anticancer Res. 1998, 18 (5A): 3181-3185.PubMedGoogle Scholar
- Van der Gaast A, Splinter TA: Teniposide (VM-26) in ovarian cancer: a review. Semin Oncol. 1992, 19 (2 Suppl 6): 95-97.PubMedGoogle Scholar
- Nielsen D, Boas J, Engelholm SA, Hansen OP, Dombernowsky P: VM-26 in advanced breast cancer. A phase II trial in patients with no prior chemotherapy. Ann Oncol. 1992, 3: 377-378.PubMedGoogle Scholar
- Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH: Proliferation dependent and cell cycle-dependent differences in expression of the 170-kilodalton and 180-kilodalton forms of topoisomerase-II in NIH 3T3 cells. Cell Growth Differ. 1991, 2: 209-214.PubMedGoogle Scholar
- Nakopoulou L, Lazaris AC, Kavantzas N, Alexandrou P, Athanassiadou P, Keramopoulos A, Davaris P: DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology. 2000, 68 (3): 137-143. 10.1159/000055914.View ArticlePubMedGoogle Scholar
- Willman JH, Holden JA: Immunohist Chemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate. Prostate. 2000, 42: 280-286. 10.1002/(SICI)1097-0045(20000301)42:4<280::AID-PROS5>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
- Stathopoulos GP, Kapranos N, Manolopoulos L, Papadimitriou C, Adamopoulos G: Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck. Anticancer Res. 2000, 20: 177-182.PubMedGoogle Scholar
- Sabourin M, Osheroff N: Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by a basic, oxidized and alkylated lesions. Nucleic Acids Res. 2000, 28: 1947-1954. 10.1093/nar/28.9.1947.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen W, Zhou X, Xu Q, Guo W, Lin L: Chemosensitivity testing of oral cancer with biopsy specimens. Zhonghua Kou Qiang Yi Xue Za Zhi. 2002, 37: 404-407.PubMedGoogle Scholar
- Fountzilas G, Lim LO, Yunis AA: The inhibitory effects of teniposide and homoharringtonine on the growth of pancreatic carcinoma cells in vitro. Anticancer Res. 1988, 8: 343-346.PubMedGoogle Scholar
- Rao PN: The molecular basis of drug-induced G2 arrest inmammalian cells. Mol Cell Biochem. 1980, 29: 47-57. 10.1007/BF00230954.View ArticlePubMedGoogle Scholar
- Hartwell LH, Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science. 1989, 246: 629-634.View ArticlePubMedGoogle Scholar
- Murray WA: Creative blocks: cell-cycle checkpoints and feedback controls. Nature. 1992, 359: 599-604. 10.1038/359599a0.View ArticlePubMedGoogle Scholar
- Chen M, Beck WT: Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors Merbarone and VM-26. Cancer Res. 1995, 55: 1509-1516.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.